231296-89-2

Usage

Uses

Used in Pharmaceutical Industry:
(E)-methyl 3-(2-amino-4-(trifluoromethyl)phenyl)acrylate is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique structure, including the amino and trifluoromethyl groups, makes it a valuable building block for creating novel drugs with specific therapeutic properties.
Used in Material Science:
In the field of material science, (E)-methyl 3-(2-amino-4-(trifluoromethyl)phenyl)acrylate is used as a monomer for the development of new polymeric materials with [application reason]. (E)-methyl 3-(2-amino-4-(trifluoromethyl)phenyl)acrylate's structural features can contribute to the creation of polymers with tailored properties, such as enhanced stability, reactivity, or specific interactions with other molecules.
Used in Chemical Synthesis:
(E)-methyl 3-(2-amino-4-(trifluoromethyl)phenyl)acrylate serves as a key component in chemical synthesis, particularly for the production of complex organic molecules with [application reason]. Its versatility in reacting with other compounds and its unique functional groups make it an attractive candidate for use in the synthesis of specialty chemicals and advanced materials.

Upstream product

• 454-79-5 2-Bromo-5-trifluoromethylaniline 
• 292638-85-8 acrylic acid methyl ester 
• 6163-58-2 tris-(o-tolyl)phosphine 

Downstream Products

• 1011533-24-6 7-(trifluoromethyl)quinolin-2(1H)-one 
• 1421348-41-5 C₂₅H₂₆F₃N₃O₃ 
• 83183-56-6 2-chloro-7-(trifluoromethyl)quinoline 
• 1011533-24-6 7-(trifluoromethyl)quinolin-2-ol 

Relevant academic research and scientific papers

QUINOLINYL GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Development of CXCR3 antagonists. Part 4: Discovery of 2-amino-(4-tropinyl)quinolines

The synthesis and biological evaluation of a novel series of 2-aminoquinoline substituted piperidines and tropanes incorporating a homotropene moiety is herein described. The series exhibits potent antagonism of the CXCR3 receptor and superior physicochem

2,3-substituted indole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is tetrazolyl optionally substituted with a substituent selected from C1-4 alkyl and halosubstituted C1-4 alkyl;A is C1-6 alkylene; Q is selected from the following groups: (a) optionally substituted phenyl; (b) an optionally substituted, partially saturated, fully saturated or fully unsaturated five to six membered monocyclic group having one to three heteroatoms; and (c) an optionally substituted, bicyclic group consisting of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings independently and optionally having one to four heteroatoms; X is halogen, C1-4 alkyl, halosubstituted C1-4 alkyl, OH, C1-4 alkoxy or the like; and n is 0, 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.